Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LIF Double Nickase Plasmid (h): sc-401120-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LIF Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LIF Double Nickase Plasmid (h) and LIF Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LIF. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LIF Antibody (E-10): sc-515931
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LIF Double Nickase Plasmid (h) | sc-401120-NIC | 20 µg | $410.00 | |||
LIF Double Nickase Plasmid (h2) | sc-401120-NIC-2 | 20 µg | $410.00 |
Leukemia inhibitory factor (LIF) is a pleiotropic IL-6 family cytokine that signals through the LIFR–gp130 receptor complex to activate JAK/STAT3, MAPK/ERK, and PI3K/AKT pathways, thereby regulating cell fate decisions including proliferation, survival, and differentiation. In human cells, LIF is a key modulator of developmental and stem cell-associated programs and contributes to immune and inflammatory signaling via cytokine network crosstalk. Dysregulated LIF signaling has been linked to altered tissue remodeling and tumor-associated phenotypes such as enhanced survival, invasion, and immune modulation in multiple cancer contexts. These properties make LIF a common target for mechanistic studies of cytokine signaling, transcriptional programs downstream of STAT3, and microenvironment-driven cellular plasticity.
LIF Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LIF locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LIF. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LIF function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LIF-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.